GLI1 and neoplasm: SUFU was detected with lower expression levels in higher FIGO (International Federation of Gynaecology and Obstetrics) stages compared to lower stages [42], as the authors confirmed that the HH signaling pathway was active in ovarian tumors and that GLI1 and SUFU were associated with the tumor type and FIGO stage.